These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1062 related articles for article (PubMed ID: 33472889)

  • 1. Bladder Tumor Subtype Commitment Occurs in Carcinoma
    Wullweber A; Strick R; Lange F; Sikic D; Taubert H; Wach S; Wullich B; Bertz S; Weyerer V; Stoehr R; Breyer J; Burger M; Hartmann A; Strissel PL; Eckstein M
    Cancer Res; 2021 Mar; 81(6):1552-1566. PubMed ID: 33472889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016.
    Babjuk M; Böhle A; Burger M; Capoun O; Cohen D; Compérat EM; Hernández V; Kaasinen E; Palou J; Rouprêt M; van Rhijn BWG; Shariat SF; Soukup V; Sylvester RJ; Zigeuner R
    Eur Urol; 2017 Mar; 71(3):447-461. PubMed ID: 27324428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Seminal Vesicle Involvement by Carcinoma In Situ of the Bladder: Clonal Analysis Using Next-Generation Sequencing to Elucidate the Mechanism of Tumor Spread.
    Park HS; Shin HB; Lee MS; Kim JH; Kim SY; Park J
    Cancer Res Treat; 2020 Oct; 52(4):1283-1287. PubMed ID: 32192274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Iatrogenic pathology of the urinary bladder.
    Lopez-Beltran A; Montironi R; Raspollini MR; Cheng L; Netto GJ
    Semin Diagn Pathol; 2018 Jul; 35(4):218-227. PubMed ID: 29576423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intratumoral heterogeneity of surrogate molecular subtypes in urothelial carcinoma in situ of the urinary bladder: implications for prognostic stratification of high-risk non-muscle-invasive bladder cancer.
    Garczyk S; Bischoff F; Schneider U; Golz R; von Rundstedt FC; Knüchel R; Degener S
    Virchows Arch; 2021 Aug; 479(2):325-335. PubMed ID: 33650041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naïve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer.
    McConkey DJ; Choi W; Shen Y; Lee IL; Porten S; Matin SF; Kamat AM; Corn P; Millikan RE; Dinney C; Czerniak B; Siefker-Radtke AO
    Eur Urol; 2016 May; 69(5):855-62. PubMed ID: 26343003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Morphologic and genomic characterization of urothelial to sarcomatoid transition in muscle-invasive bladder cancer.
    Genitsch V; Kollár A; Vandekerkhove G; Blarer J; Furrer M; Annala M; Herberts C; Pycha A; de Jong JJ; Liu Y; Krentel F; Davicioni E; Gibb EA; Kruithof-de Julio M; Wyatt AW; Seiler R
    Urol Oncol; 2019 Nov; 37(11):826-836. PubMed ID: 31585777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urothelial Carcinoma In Situ (CIS): New Insights.
    Akhtar M; Al-Bozom IA; Ben Gashir M; Taha NM; Rashid S; Al-Nabet ADMH
    Adv Anat Pathol; 2019 Sep; 26(5):313-319. PubMed ID: 31149909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications.
    Wankowicz SAM; Werner L; Orsola A; Novak J; Bowden M; Choueiri TK; de Torres I; Morote J; Freeman GJ; Signoretti S; Bellmunt J
    J Urol; 2017 Oct; 198(4):817-823. PubMed ID: 28487100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A genetically defined disease model reveals that urothelial cells can initiate divergent bladder cancer phenotypes.
    Wang L; Smith BA; Balanis NG; Tsai BL; Nguyen K; Cheng MW; Obusan MB; Esedebe FN; Patel SJ; Zhang H; Clark PM; Sisk AE; Said JW; Huang J; Graeber TG; Witte ON; Chin AI; Park JW
    Proc Natl Acad Sci U S A; 2020 Jan; 117(1):563-572. PubMed ID: 31871155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic Power of a Tumor Differentiation Gene Signature for Bladder Urothelial Carcinomas.
    Mo Q; Nikolos F; Chen F; Tramel Z; Lee YC; Hayashi K; Xiao J; Shen J; Chan KS
    J Natl Cancer Inst; 2018 May; 110(5):448-459. PubMed ID: 29342309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Urethral recurrence of invasive carcinoma following BCG treatment for bladder Ca in situ].
    Ruoppolo M; Gozo M; Milesi R; Spina R; Fragapane G
    Urologia; 2010; 77 Suppl 17():72-7. PubMed ID: 21308679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The clinicopathological characteristics of muscle-invasive bladder recurrence in upper tract urothelial carcinoma.
    Shigeta K; Matsumoto K; Ogihara K; Murakami T; Anno T; Umeda K; Izawa M; Baba Y; Sanjo T; Shojo K; Tanaka N; Takeda T; Kosaka T; Mizuno R; Mikami S; Kikuchi E; Oya M
    Cancer Sci; 2021 Mar; 112(3):1084-1094. PubMed ID: 33368857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment and follow-up of superficial bladder cancer].
    Raitanen M
    Duodecim; 2002; 118(9):903-9. PubMed ID: 12238168
    [No Abstract]   [Full Text] [Related]  

  • 15. Molecular Subtypes of Urothelial Bladder Cancer: Results from a Meta-cohort Analysis of 2411 Tumors.
    Tan TZ; Rouanne M; Tan KT; Huang RY; Thiery JP
    Eur Urol; 2019 Mar; 75(3):423-432. PubMed ID: 30213523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted Next-Generation Sequencing of Flat Urothelial Lesions Reveals Putative Pathobiological Pathways, Potential Biomarkers, and Rational Therapeutic Targets.
    Musangile FY; Matsuzaki I; Iwamoto R; Sagan K; Nishikawa M; Mikasa Y; Takahashi Y; Kojima F; Hara I; Murata SI
    Mod Pathol; 2023 May; 36(5):100120. PubMed ID: 36812689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ICUD-EAU International Consultation on Bladder Cancer 2012: Non-muscle-invasive urothelial carcinoma of the bladder.
    Burger M; Oosterlinck W; Konety B; Chang S; Gudjonsson S; Pruthi R; Soloway M; Solsona E; Sved P; Babjuk M; Brausi MA; Cheng C; Comperat E; Dinney C; Otto W; Shah J; Thürof J; Witjes JA;
    Eur Urol; 2013 Jan; 63(1):36-44. PubMed ID: 22981672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Noninvasive squamous lesions in the urinary bladder: a clinicopathologic analysis of 29 cases.
    Guo CC; Fine SW; Epstein JI
    Am J Surg Pathol; 2006 Jul; 30(7):883-91. PubMed ID: 16819332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted DNA and RNA Sequencing of Paired Urothelial and Squamous Bladder Cancers Reveals Discordant Genomic and Transcriptomic Events and Unique Therapeutic Implications.
    Hovelson DH; Udager AM; McDaniel AS; Grivas P; Palmbos P; Tamura S; Lazo de la Vega L; Palapattu G; Veeneman B; El-Sawy L; Sadis SE; Morgan TM; Montgomery JS; Weizer AZ; Day KC; Neamati N; Liebert M; Keller ET; Day ML; Mehra R; Tomlins SA
    Eur Urol; 2018 Dec; 74(6):741-753. PubMed ID: 30033047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Next-Generation Sequencing Reveals Potential Predictive Biomarkers and Targets of Therapy for Urothelial Carcinoma in Situ of the Urinary Bladder.
    Garczyk S; Ortiz-Brüchle N; Schneider U; Lurje I; Guricova K; Gaisa NT; Lorsy E; Lindemann-Docter K; Heidenreich A; Knüchel R
    Am J Pathol; 2020 Feb; 190(2):323-332. PubMed ID: 31734230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 54.